United Kingdom

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

6:15pm BST
Change (% chg)

$-0.89 (-2.15%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Wed, May 9 2018

Biohaven plunges as investors pit migraine data against Allergan's drug

Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.

Biohaven tumbles as migraine drug efficacy fails to impress investors

March 26 Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.

BRIEF-Biohaven Pharmaceutical Q4 Loss Per Share $0.75

March 6 Biohaven Pharmaceutical Holding Company Ltd:

Select another date: